NCT01544361View on ClinicalTrials.gov

A Phase 1 Study to Evaluate the Safety of MEDI7814 in Adult Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions
Healthy Subjects
Interventions
OTHER

Placebo

A single dose of placebo matched to MEDI7814 intravenous infusion over at least 60 minutes on Day 1.

BIOLOGICAL

MEDI7814, 1 MG/KG

A single dose of MEDI7814, 1 mg/kg intravenous infusion over at least 60 minutes on Day 1.

BIOLOGICAL

MEDI7814, 3 MG/KG

A single dose of MEDI7814, 3 mg/kg intravenous infusion over at least 60 minutes on Day 1.

BIOLOGICAL

MEDI7814, 10 MG/KG

A single dose of MEDI7814, 10 mg/kg intravenous infusion over at least 60 minutes on Day 1.

BIOLOGICAL

MEDI7814, 20 MG/KG

A single dose of MEDI7814, 20 mg/kg intravenous infusion over at least 60 minutes on Day 1.

Trial Locations (1)

Unknown

Research Site, Omaha

Sponsors

Lead Sponsor

MedImmune LLC
All Listed Sponsors
lead

MedImmune LLC

INDUSTRY